- Cloudbreak Pharma flagged a compliance breach tied to use of proceeds from fiscal 2025 IPO, citing a temporary deviation from prospectus allocation.
- HKD 47 million of net proceeds funded a July 3, 2025 subscription in North Rock Fund SPC, later classified as fair-value financial assets rather than cash equivalents.
- Board ordered immediate redemption, sending request on March 30, 2026; fund processing redemption as of announcement date.
- Transaction met Hong Kong Listing Rules threshold for a discloseable transaction, triggering reporting and announcement requirements that were not met on time.
- Company tightened controls via staff recirculation of procedures, compliance training, enhanced consultation with legal, audit, compliance advisers.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cloudbreak Pharma Inc. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260330-12080589), on March 30, 2026, and is solely responsible for the information contained therein.
Comments